Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1800 - Molecular profiling of locally advanced/metastatic olfactory neuroblastomas


09 Oct 2016


Poster display


Zoran Gatalica


Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376


Z. Gatalica1, A. Ghazalpour1, J. Swensen1, R. Bender1, S. Vranic2, R. Feldman1, S. Reddy1

Author affiliations

  • 1 Pathology, Caris Life Sciences, 85040 - Phoenix/US
  • 2 Pathology, Clinical Centre of Sarajevo University, 71000 - Sarajevo/BA


Abstract 1800


Olfactory neuroblastoma (esthesioneuroblastoma) [ONB] is a rare malignant neoplasm arising from the olfactory epithelium in the nasal vault. It usually takes an aggressive clinical course for which there are no specific treatment guidelines. Pursuing the goals of personalized medicine, we investigated a cohort of recurrent and/or metastatic ONBs using multiplatform molecular profiling approach.


Formalin-fixed paraffin-embedded tissue samples of twenty (10 male, 10 female patients, age range: 29-84 years) ONBs were profiled at Caris Life Sciences (Phoenix, Arizona) using DNA sequencing (Sanger sequencing, massively parallel sequencing [Illumina NGS] and gene fusions [Archer FusionPlex]), whole genome RNA microarray (HumanHT-12 v4 beadChip, Illumina), gene copy number assays (chromogenic and fluorescent in situ hybridization) and immunohistochemistry.


Mutations were detected in 8/14 (57%) ONBs including TP53 (3 cases), CTNNB1 (2 cases), APC, cKIT, cMET and PDGFRA, and SMAD4 gene (single cases, respectively). When compared with control tissues, 21 genes were over expressed and 19 genes under expressed by microarray assay (>10x). Some of the upregulated genes included stem cell marker CD24, SCG2 (Secretogranin II) and Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2). None of the cases harbored copy number variations of EGFR, HER2 and cMET genes, and no gene fusions were identified. No case expressed PD-L1 (0/6) or IDO-1 (0/3). Multiple protein biomarkers of response or resistance to classic chemotherapy drugs were identified: low ERCC1 [cisplatin sensitivity] in 82% (9/11), high TOPO1 [irinotecan sensitivity] in 63% [12/19], high TUBB3 [vincristine resistance] in 92% (12/13) and high MRP1 (multidrug resistance) in 100% (6/6).


Our study indicates that a subset of ONBs exhibits molecular alterations, notably in the Wnt and cKIT/PDGFRA pathways, that are potentially treatable using novel targeted therapies. Optimization of cytotoxic chemotherapy approaches based on protein expression may be worthy of further investigation.

Clinical trial identification

Not applicable.

Legal entity responsible for the study

Caris Life Sciences, Phoenix, Arizona, USA


Caris Life Sciences, Phoenix, Arizona, USA


Z. Gatalica, A. Ghazalpour, J. Swensen, R. Bender, R. Feldman, S. Reddy: Employee of Caris Life Sciences. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings